Eicosa-9,12,15-trienoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Eicosa-9,12,15-trienoic acid
• 英文别名: icosa-9,12,15-trienoic acid
• 化学式: C₂₀H₃₄O₂
• 分子量: 306.5
• InChiKey: CAFPYRQXMDDJST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  22
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME
  申请人：PLx Opco Inc.

  公开号：US20220000886A1

  公开（公告）日：2022-01-06

  Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system. The carriers are capable of pH dependent release of biologically active agents and assembly or reassembly when the carrier transitions from a low pH environment, to a high pH environment and back to a low pH environment.
• ALBUMIN COMPOSITIONS AND METHODS OF PRODUCING AND USING SAME
  申请人：Albcura Corporation

  公开号：US20220048976A1

  公开（公告）日：2022-02-17

  Disclosed herein are albumin compositions having defined fatty acid profiles and methods of using the same. The albumin compositions described herein are suitable for use in cell culture methods, protein stabilization methods, amongst others. The albumin compositions described herein may improve the viability of and/or promote the growth of cells (e.g., mammalian cells) when the cells are cultured in a medium containing the albumin compositions. The albumin compositions described herein may improve the stability of a biologic when the biologic is in the presence of the albumin compositions. Further provided herein are methods of formulating albumin compositions having defined fatty acid profiles as described herein.
• NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION
  申请人：VICORE PHARMA AB

  公开号：US20220202729A1

  公开（公告）日：2022-06-30

  According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.
• [EN] PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME<br/>[FR] SUPPORTS PHARMACEUTIQUES APTES À LA RECONSTITUTION DÉPENDANTE DU PH ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：PLX OPCO INC

  公开号：WO2021195319A1

  公开（公告）日：2021-09-30

  Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system. The carriers are capable of pH dependent release of biologically active agents and assembly or reassembly when the carrier transitions from a low pH environment, to a high pH environment and back to a low pH environment.
• [EN] NEW CAPSULE COMPOSITION FOR PERORAL ADMINISTRATION<br/>[FR] NOUVELLE COMPOSITION DE CAPSULE POUR ADMINISTRATION PERORALE
  申请人：VICORE PHARMA AB

  公开号：WO2021214486A1

  公开（公告）日：2021-10-28

  According to the invention there is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a heterogeneous mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazoi-1- ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pbarmaceutically-acceptab!e salt thereof, suspended in a pbarmaceutically- acceptable, hydrophobic, lipid-based carrier in which C21 or salt thereof is essentially insoluble, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carriers include triglycerides. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.